Day: November 18, 2024

Downing LLPLEI: 213800G3X76VBG9SB50418 November 2024Form 8.3 re. Volex plc PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Downing LLP(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):Client funds managed by Downing LLPVT Downing Global Investors Fund(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:Volex Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: n/a(e)   Date position held/dealing undertaken:18 November 2024(f)   In addition to the company in 1(c) above, is the discloser making...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree VOLEX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Rising incidence of cancer around the world is projected to primarily augment the demand for CAR T-cell therapy (CAR-T (Chimeric Antigen Receptor T-cell) therapy) over the coming years. Westford, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) — CAR T-Cell Therapy Market size was valued at USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031). Due to its extraordinary efficacy in combating hematological malignancies such as non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL), the acceptance of CAR T-cell therapy has considerably increased, thereby enhancing the prospects of growth in the industry. CAR T cell therapy is a treatment that concentrates on healthy cells within the body and only attacks the cancerous cells. These benefits are expected to boost growth...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree VOLEX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...